AbbVie (NYSE:ABBV) Stock Falls 1% – What’s Next?

AbbVie Inc. (NYSE:ABBV) dropped 1% on Tuesday. The stock traded as low as $284.70 and last traded at $285.88. Approximately 5,336,668 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 6,328,662 shares. The stock had previously closed at $288.84.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 guidance to adjusted EPS of $13.95–$13.99 and revenue of $67.8 billion, both modestly above prior expectations. Strong performance from newer immunology medicines, including Skyrizi and Rinvoq, has helped offset Humira’s decline. Article: ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: A global licensing agreement with Brise Pharmaceuticals adds a next-generation migraine candidate to AbbVie’s pipeline; the deal could be worth as much as $757 million. Analysts also raised price targets following the company’s quarterly results, reflecting optimism about its growth transition. Article: AbbVie License Deal With Brise Potentially Valued at $757 Million Article: Analysts Increase Their Forecasts on AbbVie
• Neutral Sentiment: Allergan Aesthetics plans to present research at the ASDS 2026 meeting, including data on aesthetic treatments following medical weight loss. The update signals continued investment in the business but does not indicate an immediate change to earnings. Article: Allergan Aesthetics to Present New Research at ASDS 2026
• Negative Sentiment: AbbVie’s fourth-quarter adjusted EPS guidance of $3.83–$3.87 is below the $3.89 consensus estimate, despite revenue guidance slightly above expectations. Commentary also flags a potentially stretched valuation after a strong year, which could make the shares more sensitive to any growth disappointment. Article: AbbVie Hit a New High After Earnings. There’s More Upside Left.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price target for the company from $235.00 to $300.00 in a report on Thursday, August 13th. BNP Paribas Exane boosted their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group upped their target price on shares of AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday. Scotiabank lifted their price target on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $275.00 price objective on shares of AbbVie in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $294.67.

AbbVie Price Performance

The firm has a market cap of $505.09 billion, a price-to-earnings ratio of 49.20, a P/E/G ratio of 1.31 and a beta of 0.24. The firm’s fifty day moving average is $269.81 and its two-hundred day moving average is $237.57.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the company earned $1.86 EPS. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s dividend payout ratio is presently 119.10%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Institutional Trading of AbbVie

Several institutional investors have recently modified their holdings of the company. Ethos Capital Management Inc. grew its holdings in AbbVie by 12.1% during the third quarter. Ethos Capital Management Inc. now owns 11,531 shares of the company’s stock worth $3,017,000 after buying an additional 1,248 shares in the last quarter. Sierra Ocean LLC bought a new position in AbbVie during the 3rd quarter valued at $215,000. Verus Capital Partners LLC boosted its holdings in AbbVie by 0.5% during the 3rd quarter. Verus Capital Partners LLC now owns 48,145 shares of the company’s stock worth $12,594,000 after acquiring an additional 216 shares during the last quarter. AlphaCentric Advisors LLC boosted its holdings in AbbVie by 1.9% during the 3rd quarter. AlphaCentric Advisors LLC now owns 3,683 shares of the company’s stock worth $963,000 after acquiring an additional 70 shares during the last quarter. Finally, Abacus Wealth Partners LLC grew its stake in shares of AbbVie by 9.5% in the 3rd quarter. Abacus Wealth Partners LLC now owns 8,795 shares of the company’s stock worth $2,301,000 after acquiring an additional 766 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.